Bringing the Oncology Community Together

Dr. Zaks on Patient-Reported Symptom Assessments

Tal Zaks, MD, PhD
Published Online: Friday, May 24, 2013
Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, discusses patient-reported symptom assessment in the phase III JAKARTA trial of SAR302503 for myelofibrosis.

The benefit of patient-reported symptom assessment is self-evident, Zaks said. When designing a treatment that alleviates patient symptoms, the best way to know if it's working is by asking the patient if they're feeling better. Patient-reported assessments are not trivial: Zaks said the research team had to build good questions specifically for myelofibrosis that have since been validated by the regulatory authorities.

The idea to capture patient symptoms in real-time without a clinician will make it a powerful tool to demonstrate a difference in symptoms.

Related Articles
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Epizyme Maintains Independence, Advances HMT-Inhibitor Platform
Epizyme, a Cambridge, Massachusetts-based biotech, opted for independence, with a successful IPO in 2013.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.